Summary of Key Points Core Viewpoint - On October 29, Hangzhou Oxygen Plant Co., Ltd. disclosed an increase in shareholding, while 11 A-share listed companies announced plans for share reductions [1][2]. Group 1: Shareholding Increases - Hangzhou Oxygen Plant received a stake increase from CITIC Financial Assets, raising its holding to 5% [2]. Group 2: Shareholding Reductions - Greenfield Machinery: Shareholder Shao Yutian plans to reduce holdings by no more than 3% [2]. - Jianghua Micro: Shareholder Yin Fuhua intends to reduce holdings by no more than 3% [2]. - Jiuzhou Group: Shareholders plan to collectively reduce holdings by no more than 1.88% [2]. - Guorui Technology: Shareholder Gong Ruiliang plans to reduce holdings by no more than 3% [2]. - Kairun Co., Ltd.: Shareholder Li Zhongren plans to reduce holdings by no more than 1.70% [2]. - Yingjixin: Shareholder plans to transfer 2.9% of company shares through inquiry [2]. - Mindong Electric: Shareholder Provincial Investment Group intends to reduce holdings by no more than 1% [2]. - WuXi AppTec: Shareholders controlled by the actual controller plan to reduce holdings by no more than 2% [2]. - Zhongwei Company: A dedicated repurchase account plans to reduce holdings by no more than 0.33% [2]. - Jinhua Co., Ltd.: Plans to reduce no more than 746.54 million shares that have been repurchased [2]. - Hechuan Technology: Bosch China intends to reduce holdings by no more than 3% [2].

| | | 10.29上市公司盘后增持情况 | | --- | --- | --- | | 1 | 杭氧股份 | 获中信金融资产举牌 持股比例达5% | | | | 10.29上市公司盘后减持情况 | | 1 | 绿田机械 | 股东邵雨田计划减持不超3%公司股份 | | 2 | 江化微 | 股东殷福华计划减持不超3%股份 | | 3 | 九州集团 | 股东拟合计减持不超1.88%股份 | | 4 | 国瑞科技 | 股东龚瑞良计划减持不超3%公司股份 | | 5 | 凯伦股份 | 股东李忠人计划减持不超1.70%公司股份 | | 6 | 英集芯 | 股东计划询价转让2.9%公司股份 | | 7 | 闽东电力 | 股东省投集团拟减持不超1%股份 | | 8 | 药明康德 | 实际控制人控制的股东拟减持不超过2%公司股份 | | g | 中微公司 | 回购专用证券账户拟减持不超0.33%股份 | | 10 | 金花股份 | 拟减持不超过746.54万股已回购股份 | | 11 | 天川科技 | 博世中国拟减持不超3%公司股份 | MACD金叉信号形成，这些股涨势不错！ 炒股就看金麒麟分析师研报，权威，专业，及时，全 ...

Core Viewpoint - WuXi AppTec (603259) announced on October 29 that its actual controller's shareholder plans to reduce its holdings of A-shares by up to 2% of the total share capital within three months, starting 15 trading days after the announcement due to personal funding needs [1] Summary by Sections - **Shareholder Reduction Plan** - The actual controller's shareholder intends to reduce its A-share holdings through centralized bidding and/or block trading [1] - The maximum number of shares to be reduced will not exceed 2% of the company's total share capital [1] - **Current Shareholding Status** - As of the announcement date, the actual controller's shareholder holds a total of 543 million A-shares, representing 18.211% of the company's total share capital [1]

人民财讯10月29日电，药明康德（603259）10月29日公告，实际控制人控制的股东合计持有公司 18.211%股份，计划通过集中竞价和/或大宗交易方式减持公司A股股份，减持股份数量不超过公司总股 本的2%，即合计不超过5967.51万股。 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603259 证券简称：药明康德 公告编号：临 2025-070 无锡药明康德新药开发股份有限公司 股东减持股份计划公告 股东持股的基本情况 截至本公告披露日，无锡药明康德新药开发股份有限公司（以下简称"公 司"）实际控制人控制的股东合计持有公司 A 股股份 543,364,675 股，占公司截 至本公告日总股本的 18.211%。该等股份均为公司首次公开发行 A 股股票并上市 前所取得的股份及上市后权益分派资本公积转增股本方式取得的股份，已自 2021 年 5 月 10 日起上市流通。 减持计划的主要内容 公司于 2025 年 10 月 29 日收到实际控制人控制的股东发出的《告知函》。因 自身资金需求，公司实际控制人控制的股东计划根据市场情况自本公告披露日起 15 个交易日后的 3 个月内，通过集中竞价和/或大宗交易方式减持公司 A 股股份， 减持股份数量不超过公司总股本的 2%，即合计不超过 59,675,143 股。其中：拟 通过集中竞 ...

集中竞价减持上限：任意连续90日内不超过总股本1%（29,837,571股）；大宗交易减持上限为2%。 药明康德（603259）股东减持股份计划公告要点解读 股东基本情况：截至公告日，公司实际控制人控制的股东合计持有公司A股543,364,675股，占总股本 18.211%（总股本2,983,757,155股）。 减持计划：实际控制人控制的股东拟自公告披露日起15个交易日后的3个月内，减持不超过公司总股本 2%（即59,675,143股），通过集中竞价和/或大宗交易方式实施。 主要减持股东及数量：G&C IV Hong Kong Limited等多家主体，单一主体减持比例均不超过0.526%，具 体减持数量详见公告。 减持原因：均为自身资金需求。 减持期间：2025年11月20日至2026年2月17日。 风险提示：本次减持不会导致公司控制权变更，减持数量和价格存在不确定性，股东将严格遵守相关法 律法规。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年10月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-070 无锡药明康德新药开发股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 ...

Core Insights - WuXi AppTec, a leading Chinese biopharmaceutical outsourcing (CXO) company, reported strong financial results for the first three quarters of 2025, with revenue of 32.857 billion yuan, a year-on-year increase of 18.61%, and a net profit of 12.076 billion yuan, up 84.84% [1][4] - The company announced a significant asset divestiture, selling its clinical research subsidiaries for 2.8 billion yuan, which is interpreted as a strategic move to focus on core business areas amid a challenging international environment [1][5] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 32.857 billion yuan, a growth of 18.61% year-on-year, and a net profit of 12.076 billion yuan, reflecting an 84.84% increase [1][4] - The third quarter alone saw revenue of 12.057 billion yuan, up 15.26%, and a net profit of 3.515 billion yuan, which is a 53.27% increase [1] - The cash flow from operations reached 10.87 billion yuan, marking a 35% increase year-on-year [1] Business Segments - The chemical business segment emerged as the largest contributor to revenue, generating 25.978 billion yuan, a year-on-year increase of 29.28% [3] - The TIDES business (oligonucleotides and peptides) showed exceptional performance, with revenue reaching 7.84 billion yuan, a staggering growth of 121.1% [3] - The small molecule CRDMO business demonstrated a "funnel effect," successfully synthesizing and delivering over 430,000 new compounds in the past 12 months [4] Strategic Moves - The divestiture of the clinical research subsidiaries is seen as a strategic choice to optimize asset structure and focus on high-margin, high-growth areas like the chemical and TIDES businesses [5][7] - The sale of these subsidiaries, which contributed only about 3.5% of total revenue, allows the company to concentrate resources on its core CRDMO business [5][7] - The transaction includes a performance-based payment structure, allowing the company to benefit from future growth of the divested assets [7] Market Context - The backdrop of the company's performance includes ongoing geopolitical tensions and the looming threat of the U.S. Biodefense Act, which could significantly impact Chinese biotech firms [8][10] - Despite these challenges, revenue from U.S. clients grew by 31.9%, with North America accounting for 64% of total revenue [10][11] - The company is diversifying its market presence, with European client revenue increasing by 13.5% and stable growth in China and other markets [11][12] Market Reaction - Following the announcement of the asset divestiture, the company's stock prices rose, reflecting positive market sentiment towards its strong quarterly performance and strategic adjustments [12]

Core Viewpoint - WuXi AppTec's major shareholders plan to reduce their holdings by up to 59.6751 million shares, representing no more than 2% of the company's total share capital, starting from November 20, 2025, due to personal funding needs [1] Summary by Category - **Shareholder Reduction Plan** - The reduction will occur through centralized bidding and block trading methods, with a maximum of 29.8376 million shares to be sold via centralized bidding and up to 59.6751 million shares through block trading [1] - **Reason for Reduction** - The primary reason for this share reduction is the personal funding needs of the shareholders involved [1] - **Implementation Uncertainty** - The implementation of this reduction plan carries uncertainties [1]

Core Viewpoint - WuXi AppTec's actual controller and shareholders hold a total of 543 million A-shares, accounting for 18.211% of the company, and plan to reduce their holdings by up to 59.6751 million shares due to personal funding needs [1] Summary by Category - **Shareholding Structure** - The actual controller and shareholders of WuXi AppTec collectively hold 543 million A-shares, representing 18.211% of the total shares [1] - **Planned Share Reduction** - The shareholders intend to reduce their holdings from November 20, 2025, to February 17, 2026, through centralized bidding and/or block trading, with a total reduction not exceeding 59.6751 million shares, which is up to 2% of the company's total share capital [1] - The reduction includes a maximum of 29.8376 million shares through centralized bidding and up to 59.6751 million shares through block trading [1]